Roche Says Phase 3 Studies for Alzheimer's Drug Failed to Meet Primary Endpoints
By Pierre Bertrand Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimers disease, failed to meet its primary endpoints. The Swiss... | November 14, 2022
Pierre Bertrand Roche Holding Clinical Trials Dow Jones Roche Holding Ag Stock Exchange Press Release
Source: marketscreener.com